ALLO

Allogene Therapeutics, Inc. | Cotação de Ações

Última atualização31/01/2025, 18:00:02

PreçoUS$ 1,80

Variação (dia)-US$ 0,12 (-6.25%)▼

Min. 52 SemanasUS$ 1,78

Máx. 52 SemanasUS$ 5,78

Capitalização de mercado--

Endereço: 210 East Grand Avenue, South San Francisco, CA, 94080

Telefone: 650 457 2700

Funcionários: 232

Allogene Therapeutics, Inc.ALLO

US$ 1,80

- 0,126,3%

31/01/2025 18:00:02

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 1,80

Valor de mercado--

AberturaUS$ 1,94

Preço máximoUS$ 2,00

Preço mínimoUS$ 1,78

VolumeUS$ 2,6 mi

Fechamento anteriorUS$ 1,92

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Ações relacionadas

Atara Biotherapeutics, Inc.

ATRA ▼0.84% | US$ 5,73

Fate Therapeutics, Inc.

FATE ▲0.04% | US$ 1,31

Apellis Pharmaceuticals, Inc.

APLS ▲0.46% | US$ 30,39

BridgeBio Pharma, Inc.

BBIO ▲0.84% | US$ 34,63

Allakos Inc.

ALLK ▲0.12% | US$ 0,97

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.

Saiba mais sobre a brapi e nossa missão de fornecer informações confiáveis

Entenda a missão da brapi em fornecer informações estritamente informativas de fontes confiáveis. Valorizamos a transparência e a responsabilidade, incentivando investidores a buscar aconselhamento financeiro independente para decisões informadas.